Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Nycomed/Takeda Adds Antihistamine to China Portfolio

publication date: Sep 30, 2011
Nycomed, the Swiss biopharma being acquired by Takeda, has bought China marketing rights of an antihistamine from Almirall SA of Spain. Kestine is a member of the ebastine class of H1 inhibitors that do not cause drowsiness in users. At the same time, Takeda announced the closing of its $13 billion takeover of Nycomed, giving Takeda increased access to emerging markets such as China. More details....

Stock Symbols: (TSE: 4502) (BMAD: ALM)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital